| |
 |
|
|
|
|
|
Poster: 8
Visits: 93
Title: Phase II Study of Tivantinib (ARQ 197) in Combination with Cetuximab in EGFR Inhibitor-resistant, MET-High, KRAS Wild-Type (KRASwt) Metastatic Colorectal Cancer (mCRC)
Authors: Lorenza Rimassa , Silvia Bozzarelli, Stefano Cordio, Laura Toppo, Sara Lonardi, Alberto Zaniboni, Roberto Bordonaro, Wanda Liguigli, Vittorina Zagonel, Maria Chiara Tronconi, Luca Di Tommaso, Laura Giordano, Armando Santoro
Centre: Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano (Milan)
|
|
You must be registered to reply or comment.
|
|
PHASE II STUDY OF TIVANTINIB (ARQ 197) IN COMBINATION WITH CETUXIMAB IN EGFR INHIBITOR-RESISTANT, MET-HIGH, KRAS WILD-TYPE (KRASWT) METASTATIC COLORECTAL CANCER (MCRC)
|
|
| You must be registered to reply or comment. |
|
|
|
|
|
|
| Most viewed poster for this congress |
|
|
Poster: 98
Visits: 485
Title: LOCAL ADVANCED GASTRIC CANCER: OPTIMIZATION OF MANAGEMENT
Authors: Oleg Kshivets ,
Centre: surgery department, Kaluga Cancer Center
|
|
|
|
|
|
|
| Poster most viewed in this topic |
|
|
Poster: 14
Visits: 322
Title: First-line treatment with modified FOLFOX6 (mFOLFOX6) panitumumab or bevacizumab in patients with RAS/BRAF wild-type metastatic colorectal carcinoma
Authors: Fernando Rivera ,
Centre: Hospital Universitario Marqués de Valdecilla
|
|
|
|
